NCT01943292View on ClinicalTrials.gov

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 2, 2013

Primary Completion Date

June 9, 2014

Study Completion Date

June 9, 2014

Conditions
Non Hematologic Cancers
Interventions
DRUG

Defactinib

Trial Locations (1)

Unknown

Kinki University Hospital, Osaka

All Listed Sponsors
lead

Verastem, Inc.

INDUSTRY

NCT01943292 - Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies | Biotech Hunter | Biotech Hunter